Trastuzumab Emtansine
ERBB3 Gene Mutation
M.D. Anderson Cancer Centerantibody_drug_conjugatePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
7 Active assets in the ERBB3 Gene Mutation cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Capecitabine M.D. Anderson Cancer Center | Phase 1 | CC |
TRASTUZUMAB M.D. Anderson Cancer Center | Phase 1 | CC |
Neratinib M.D. Anderson Cancer Center | Phase 1 | CC |
Everolimus M.D. Anderson Cancer Center | Phase 1 | CC |
Vinorelbine M.D. Anderson Cancer Center | Phase 1 | CC |
Palbociclib M.D. Anderson Cancer Center | Phase 1 | CC |
gsk1120212 M.D. Anderson Cancer Center | Phase 1 | CC |
Same molecule, other indications
Trastuzumab Emtansine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →